Total Payments
$3,472
2024 Payments
$834.88
Companies
27
Transactions
189
Medicare Patients
3,917
Medicare Billing
$432,122
Payment Breakdown by Category
Food & Beverage$3,270 (94.2%)
Education$202.33 (5.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,270 | 185 | 94.2% |
| Education | $202.33 | 4 | 5.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,169 | 72 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $305.30 | 18 | $0 (2024) |
| PFIZER INC. | $248.02 | 13 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $199.49 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $190.91 | 5 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $150.15 | 11 | $0 (2021) |
| Boston Scientific Corporation | $144.74 | 3 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $110.37 | 5 | $0 (2019) |
| Covidien LP | $106.30 | 2 | $0 (2019) |
| Celltrion USA Inc. | $102.08 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $834.88 | 48 | ABBVIE INC. ($164.20) |
| 2023 | $567.56 | 34 | AbbVie Inc. ($223.53) |
| 2022 | $438.24 | 25 | ABBVIE INC. ($237.59) |
| 2021 | $434.16 | 28 | AbbVie Inc. ($151.29) |
| 2020 | $84.33 | 6 | AbbVie Inc. ($30.76) |
| 2019 | $546.13 | 23 | AbbVie, Inc. ($152.24) |
| 2018 | $366.49 | 20 | AbbVie, Inc. ($209.45) |
| 2017 | $200.55 | 5 | Janssen Biotech, Inc. ($99.95) |
All Payment Transactions
189 individual payment records from CMS Open Payments — Page 4 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/07/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $11.78 | General |
| Category: VIROLOGY | ||||||
| 06/01/2023 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $3.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/09/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $12.69 | General |
| Category: THERAPY FOR CSID | ||||||
| 05/05/2023 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/07/2023 | RedHill Biopharma Inc. | — | Food and Beverage | Cash or cash equivalent | $17.96 | General |
| 03/01/2023 | PFIZER INC. | XELJANZ (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/14/2022 | PFIZER INC. | XELJANZ (Drug), COMIRNATY, PAXLOVID | Food and Beverage | In-kind items and services | $12.94 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/01/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/04/2022 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $7.66 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/27/2022 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/26/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/26/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.54 | General |
| Category: IMMUNOLOGY | ||||||
| 10/13/2022 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/15/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/13/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 08/18/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/07/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: IMMUNOLOGY | ||||||
| 06/20/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/14/2022 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/27/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 04/21/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: IMMUNOLOGY | ||||||
| 04/13/2022 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/08/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: IMMUNOLOGY | ||||||
| 03/22/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $49.65 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,597 | 2,057 | $808,454 | $187,412 |
| 2022 | 20 | 1,119 | 1,420 | $505,751 | $117,926 |
| 2021 | 22 | 867 | 946 | $494,894 | $89,467 |
| 2020 | 11 | 334 | 371 | $291,863 | $37,317 |
Total Patients
3,917
Total Services
4,794
Medicare Billing
$432,122
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 3 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 27 | 27 | $32,748 | $5,237 | 16.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 51 | $5,908 | $2,830 | 47.9% |
| 43264 | Removal of stone or debris from bile or pancreatic duct using a flexible endoscope via mouth | Facility | 2021 | 12 | 13 | $21,308 | $2,699 | 12.7% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 20 | 20 | $21,716 | $2,590 | 11.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 26 | 26 | $7,328 | $2,589 | 35.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 33 | $5,328 | $2,585 | 48.5% |
| 43238 | Ultrasound guided needle aspiration or biopsies of esophagus using an endoscope | Facility | 2021 | 14 | 14 | $21,898 | $2,473 | 11.3% |
| 43237 | Ultrasound examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 17 | 17 | $12,861 | $2,198 | 17.1% |
| 43246 | Insertion of stomach tube using an endoscope | Facility | 2021 | 15 | 15 | $19,833 | $2,075 | 10.5% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 11 | 12 | $14,928 | $1,862 | 12.5% |
| 43249 | Balloon dilation of esophagus, stomach and upper small bowel using a flexible endoscope | Facility | 2021 | 16 | 18 | $32,647 | $1,772 | 5.4% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 21 | 21 | $2,607 | $1,016 | 39.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 13 | 13 | $1,220 | $532.68 | 43.7% |
| 74328 | Radiological supervision and interpretation of insertion of catheter into biliary duct using an endoscope | Facility | 2021 | 17 | 17 | $1,513 | $383.01 | 25.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 61 | 63 | $22,381 | $10,080 | 45.0% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 37 | 37 | $74,333 | $4,943 | 6.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 48 | 75 | $8,916 | $4,276 | 48.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 42 | 42 | $84,378 | $3,231 | 3.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 33 | $5,066 | $2,790 | 55.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 21 | 21 | $4,410 | $2,521 | 57.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 31 | 31 | $6,200 | $2,355 | 38.0% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 21 | 24 | $38,328 | $2,305 | 6.0% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 14 | 14 | $22,924 | $1,906 | 8.3% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 19 | 20 | $22,920 | $1,714 | 7.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $2,007 | $1,196 | 59.6% |
About Avery Smith
Avery Smith is a Gastroenterology healthcare provider based in Abilene, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2014. The National Provider Identifier (NPI) number assigned to this provider is 1578983771.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Avery Smith has received a total of $3,472 in payments from pharmaceutical and medical device companies, with $834.88 received in 2024. These payments were reported across 189 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($3,270).
As a Medicare-enrolled provider, Smith has provided services to 3,917 Medicare beneficiaries, totaling 4,794 services with total Medicare billing of $432,122. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Abilene, TX
- Active Since 04/27/2014
- Last Updated 01/11/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1578983771
Products in Payments
- Humira (Biological) $272.39
- RINVOQ (Biological) $235.86
- XELJANZ (Drug) $212.18
- DUPIXENT (Biological) $199.49
- MAVYRET (Drug) $161.98
- LINZESS (Drug) $139.31
- DIFICID (Drug) $136.97
- ENTYVIO (Biological) $120.60
- CREON (Drug) $112.88
- Kanuma (Drug) $110.37
- HYDRATOME (Device) $108.68
- REMICADE (Biological) $99.95
- TREMFYA (Drug) $90.96
- Entyvio (Biological) $87.81
- ELEVIEW (Device) $81.78
- OCALIVA (Drug) $78.47
- VEGZELMA (Biological) $78.46
- HUMIRA (Biological) $73.36
- VOWST (Biological) $71.58
- XIFAXAN (Drug) $65.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.